Altre lingue Theriva Biologics, Inc.

Azioni

TOVX

US87164U4094

Mercato chiuso - Nyse Altri mercati azionari 22:00:00 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,403 ^USD	-3,59%		-3,93%	-6,30%

23/04	Theriva Biologics annuncia dati topline positivi dallo studio di Fase 1 sponsorizzato da un ricercatore su VCN-01 intravitreale in pazienti pediatrici con retinoblastoma refrattario	CI
25/03	Transcript : Theriva Biologics, Inc., 2023 Earnings Call, Mar 25, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	25/04
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	23/04
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	23/04
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting	22/04
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting	08/04
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results	25/03
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
North American Morning Briefing : Tech in Focus on -2-	25/03
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results	19/03
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference	11/03
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	07/02
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	07/02
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference	16/01
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results	13/11
North American Morning Briefing : Stock Futures -2-	13/11
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results	06/11
Theriva™ Biologics to Participate in the BIO-Europe Conference	02/11
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	02/11
Theriva?? Biologics and Sant Joan de Deu-Bar Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	02/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Theriva Biologics, Inc.

Azioni

TOVX

US87164U4094

Altre lingue

Filtri